Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation

Figure 8

A schematic model of the involvement of signal molecules in etifoxine-mediated IR and lipid metabolism under HCV infection. Etifoxine itself rescued the HCV-mediated lower MMP, aggravated the HCV-impeded activations of IRS-1 and Akt, and inhibited the HCV-induced lipid accumulation accompanied with downregulation of SREBP-1 and apoJ. Alternatively, etifoxine blocked the insulin-mediated IRS-1/Akt signals, FoxO1 translocation, and glucose uptake. Dotted lines with arrows indicated the up- or downregulation of HCV-mediated signal molecules. Bold solid lines with arrows indicated the increased levels, decreased levels, or blockade of HCV-mediated signal molecules by etifoxine.